



Patient ID SA00135880	Patient Name SAMPLEREPORT, FPALI A	Birth Date 1995-07-16	Gender M	Age 25
Order Number SA00135880	Client Order Number SA00135880	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 24 Aug 2020 14:00		

Paliperidone, Serum

Paliperidone

Y082

10 ng/mL

Reporting Limit: 1.0 ng/mL

Synonym(s): Invega(R)

Paliperidone (9-hydroxyrisperidone) is the active ingredient in Invega extended-release tablets.

Paliperidone is also the major active metabolite of Risperidone. Steady-state concentrations are typically attained within 4 to 5 days of dosing.

Following daily administration of 12 mg extended release formulation, paliperidone steady state plasma concentrations ranged from 30 to 40 ng/mL.

Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

Received: 25 Aug 2020 12:33

Reported: 26 Aug 2020 09:44

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
Y082	NMS Labs	200 Welsh Road, Horsham, PA 190442208		